EyePoint, Inc. EYPT
Set alert
0.35 USD -0.03 -8.32%
At close · Oct 30
0.35 0.00 -0.34%
After hours · Oct 30, 7:58 PM ET
0.3446 Day range 0.3762
0.3484 52-week range 18.85
- YTD
- -98.09%
- 1 year
- -97.15%
- Open
- 0.37
- Prev close
- 0.38
- Mkt cap
- 29.21M
- Vol
- 6.12M
- Avg vol
- 8.97M
- EPS
- -3.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3446
- High
- 0.3762
- Forward P/E
- -4.89
- Beta
- 1.74
- Short ratio
- 11.44
- Inst. own
- 111.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 13.11
- 200-d avg
- 14.14
- 1y target
- 40.93
2Y chart
Events in this range
- Aug 6, 2025Earnings: -0.85; estimate -0.67; surprise -26.87%
- Nov 5, 2025Earnings: -0.85; estimate -0.77; surprise -10.39%
- Mar 4, 2026Earnings: -0.81; estimate -0.78; surprise -3.85%
- May 6, 2026Earnings: -0.99; estimate -0.79; surprise -25.32%
- Jun 24, 2026Rating: Guggenheim · Buy → Buy
- Jul 1, 2026Rating: Chardan Capital · Buy → Buy
- Jul 16, 2026Rating: Stifel · — → Buy
- Aug 5, 2026Earnings: -1.09; estimate -1.01; surprise -7.92%
- Aug 6, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 6, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Aug 7, 2026Rating: Chardan Capital · Buy → Buy
Signals (99)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Sep 30, 2026 | 1 month ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 8, 2026 | 1 month ago |
| RSI: Oversold | Sep 3, 2026 | 1 month ago |
| RSI: Oversold | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| RSI: Oversold | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
| SMA: Bearish | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 14, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| SMA: Bearish | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 7, 2026 | 6 months ago |
| SMA: Bearish | Apr 6, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Apr 2, 2026 | 7 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 17, 2026 | 8 months ago |
| RSI: Oversold | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Jan 23, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| RSI: Overbought | Dec 22, 2025 | 10 months ago |
| RSI: Overbought | Dec 4, 2025 | 11 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 14, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 5, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 15, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 19, 2025 | 1 year ago |
| RSI: Overbought | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| RSI: Overbought | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| RSI: Overbought | Jun 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| RSI: Overbought | Jun 3, 2025 | 1 year ago |
| MACD: Buy Signal | May 28, 2025 | 1 year ago |
| SMA: Bullish | May 27, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| SMA: Bullish | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | May 8, 2025 | 1 year ago |
| SMA: Bearish | May 7, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| SMA: Bearish | Mar 13, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 3, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 22, 2025 | 1 year ago |
| RSI: Oversold | Dec 13, 2024 | 1 year ago |
| RSI: Oversold | Dec 5, 2024 | 1 year ago |
Key statistics
- Market cap
- 1.24B
- Enterprise value
- 1.25B
- Trailing P/E
- 0.00
- Forward P/E
- -4.89
- PEG ratio
- 0.00
- Price / sales
- 443.56
- Price / book
- 37.25
- EPS (TTM)
- -3.75
- Beta
- 1.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.79M
- Revenue growth
- 161.70%
- Free cash flow
- -155.01M
- Total cash
- 45.26M
- Total debt
- 17.62M
- Return on equity
- -148.70%
- Shares outstanding
- 83.84M
- Short % of float
- 21.99%
- 50-day average
- 13.11
- 200-day average
- 14.14
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 40.93 +11647.6% upside
Now 0.3484
- Target (low)
- 20.00
- Target (mean)
- 40.93
- Target (high)
- 68.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.921.
Financials — quick view
EYPT Revenue — quarterly 507.00K
EYPT Net income — quarterly -94.47M
EYPT EPS — quarterly -1.09
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.8897 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -1.01 | -1.09 | -0.08 | -7.92% |
| May 6, 2026 | Mar 31, 2026 | -0.79 | -0.99 | -0.20 | -25.32% |
| Mar 4, 2026 | Dec 31, 2025 | -0.78 | -0.81 | -0.03 | -3.85% |
| Nov 5, 2025 | Sep 30, 2025 | -0.77 | -0.85 | -0.08 | -10.39% |
| Aug 6, 2025 | Jun 30, 2025 | -0.67 | -0.85 | -0.18 | -26.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Chardan Capital | main | Buy | Buy |
| Aug 6, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Aug 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 16, 2026 | Stifel | init | — | Buy |
| Jul 1, 2026 | Chardan Capital | main | Buy | Buy |
| Jun 24, 2026 | Guggenheim | reit | Buy | Buy |
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eyepoint.bio
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
- EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
- EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
- RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1
- Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
- Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October
- EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
Your note
Sign in to keep a note on EYPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDO GORAN A | Director | Purchase | Aug 20, 2024 | 13,150 |
| CORMORANT ASSET MANAGEMENT ,L.P | Unknown | Sale | Dec 3, 2025 | 0 |
| DICICCO WENDY FRANCES | Director | Purchase | Aug 19, 2024 | 9,967 |
| DUKER JAY S | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 9, 2026 | 187,025 |
| ELSTON GEORGE O | Chief Financial Officer | Conversion of Exercise of derivative security | May 21, 2026 | 121,691 |
| LANDIS JOHN B | Director | Conversion of Exercise of derivative security | Jan 2, 2025 | 21,400 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.62% | 8,296,375 | 122.37M | Mar 30, 2026 |
| Cormorant Asset Management, LP | 9.59% | 8,265,000 | 121.91M | Mar 30, 2026 |
| Blackrock Inc. | 8.66% | 7,463,197 | 110.08M | Jun 29, 2026 |
| Federated Hermes, Inc. | 6.59% | 5,681,052 | 83.80M | Jun 29, 2026 |
| Franklin Resources, Inc. | 5.86% | 5,048,598 | 74.47M | Mar 30, 2026 |
| Janus Henderson Group PLC | 4.18% | 3,601,168 | 53.12M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 3.21% | 2,771,487 | 40.88M | Apr 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.02% | 2,600,860 | 38.36M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.36% | 2,033,206 | 29.99M | Jun 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 2.30% | 1,982,000 | 29.23M | Apr 29, 2026 |
| Franklin Strategic Series-FRANKLIN SMALL CAP GROWTH FUND | 1.75% | 1,506,751 | 22.22M | Apr 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.44% | 1,245,583 | 18.37M | Mar 30, 2026 |